[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Eli Lilly and Company LILLY CORPORATE CENTER INDIANAPOLIS IN 46285 USA

www.lilly.com Employees: 50,000 P: 317-276-2000

Sector:

Medical

Description:

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.

Key Statistics

Overview:

Market Capitalization, $K 1,205,256,960
Enterprise Value, $K 1,238,856,960
Shares Outstanding, K 941,357
Float, K 940,039
% Float 99.86%
Short Interest, K 9,117
Short Float 0.97%
Days to Cover 3.94
Short Volume Ratio 0.44
% of Insider Shareholders 0.14%
% of Institutional Shareholders 82.53%

Financials:

Annual Sales, $ 65,179 M
Annual Net Income, $ 20,640 M
Last Quarter Sales, $ 22,974 M
Last Quarter Net Income, $ 7,095 M
EBIT, $ 33,633 M
EBITDA, $ 35,630 M

Growth:

1-Year Return 82.07%
3-Year Return 131.25%
5-Year Return 392.91%
5-Year Revenue Growth 165.61%
5-Year Earnings Growth 205.30%
5-Year Dividend Growth 102.70%

Per-Share Information:

Most Recent Earnings 8.38 on 08/05/26
Next Earnings Date 10/29/26
Earnings Per Share ttm 31.49
EPS Growth vs. Prev Qtr -1.99%
EPS Growth vs. Prev Year 32.81%
Annual Dividend & Yield (Paid) 6.69 (0.52%)
Annual Dividend & Yield (Fwd) 6.92 (0.58%)
Most Recent Dividend 1.730 on 08/14/26
Next Ex-Dividends Date 08/14/26
Dividend Payable Date 09/10/26
Dividend Payout Ratio 21.58%
Most Recent Split 2-1 on 10/16/97

LLY Ratios

Ratio
Price/Earnings ttm 38.92
Price/Earnings forward 32.55
Price/Earnings to Growth 1.40
Return-on-Equity % 97.83%
Return-on-Assets % 23.23%
Profit Margin % 31.67%
Debt/Equity 1.62
Price/Sales 17.70
Price/Cash Flow 47.07
Price/Book 32.89
Book Value/Share 35.97
Interest Coverage 3.22
60-Month Beta 0.51

LLY Dividends

Date Value
08/14/26 $1.7300
05/15/26 $1.7300
02/13/26 $1.7300
11/14/25 $1.5000
08/15/25 $1.5000
05/16/25 $1.5000
02/14/25 $1.5000
11/15/24 $1.3000
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.